ARCOMA.ST
Price:
$10.75
Market Cap:
$141.75M
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in Växjö, Sweden.
Industry
Medical - Devices
IPO Date
2014-11-14
Stock Exchange
STO
Ticker
ARCOMA.ST
According to Arcoma AB’s latest financial reports and current stock price. The company's current ROE is 14.77%. This represents a change of 296.06% compared to the average of 3.73% of the last 4 quarters.
The mean historical ROE of Arcoma AB over the last ten years is -4.35%. The current 14.77% ROE has changed -439.21% with respect to the historical average. Over the past ten years (40 quarters), ARCOMA.ST's ROE was at its highest in in the March 2024 quarter at 8.52%. The ROE was at its lowest in in the March 2016 quarter at -18.03%.
Average
-4.35%
Median
-0.65%
Minimum
-31.18%
Maximum
18.84%
Discovering the peaks and valleys of Arcoma AB ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 257.54%
Maximum Annual ROE = 18.84%
Minimum Annual Increase = -715.76%
Minimum Annual ROE = -31.18%
Year | ROE | Change |
---|---|---|
2024 | 18.84% | 257.54% |
2023 | 5.27% | 27.10% |
2022 | 4.15% | -124.43% |
2021 | -16.97% | -715.76% |
2020 | 2.76% | -81.16% |
2019 | 14.63% | -460.03% |
2018 | -4.06% | -83.10% |
2017 | -24.05% | -22.88% |
2016 | -31.18% | 141.36% |
2015 | -12.92% | -689.83% |
The current ROE of Arcoma AB (ARCOMA.ST) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
9.42%
5-year avg
2.81%
10-year avg
-4.35%
Arcoma AB’s ROE is less than Stille AB (8.95%), less than Avensia AB (publ) (57.33%), less than Genovis AB (publ.) (10.62%), greater than aXichem AB (-28.50%), greater than Dignitana AB (publ) (-222.31%),
Company | ROE | Market cap |
---|---|---|
8.95% | $2.05B | |
57.33% | $449.19M | |
10.62% | $1.87B | |
-28.50% | $163.75M | |
-222.31% | $172.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcoma AB using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcoma AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Arcoma AB's ROE?
How is the ROE calculated for Arcoma AB (ARCOMA.ST)?
What is the highest ROE for Arcoma AB (ARCOMA.ST)?
What is the 3-year average ROE for Arcoma AB (ARCOMA.ST)?
What is the 5-year average ROE for Arcoma AB (ARCOMA.ST)?
How does the current ROE for Arcoma AB (ARCOMA.ST) compare to its historical average?